Verastem (VSTM) Stock Price, News, Quotes-Moomoo

Account Info

Log Out

US Stock MarketDetailed Quotes

VSTM Verastem

Watchlist

4.2600
-0.3400-7.39%

Close Dec 18 16:00 ET

189.60MMarket Cap-1.36P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Verastem Oncology's Triplet Combination Shows No Dose-Limiting Toxicities In RAMP 203 Trial
RTTNewsDec 18 08:22 ET
Verastem Announces Preliminary Avutometinib and Sotorasib Data
TipRanksDec 18 07:35 ET
Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Announces Target Price $9
Moomoo NewsDec 18 07:34 ET · Ratings
Express News | Verastem Inc - No Dose-Limiting Toxicities Observed in Triplet Combination
ReutersDec 18 07:31 ET
Express News | Verastem Oncology Provides a Clinical Update for Ramp 203 Trial in Advanced Kras G12C Mutant Non-Small Cell Lung Cancer
ReutersDec 18 07:30 ET
Express News | Verastem Inc : Mizuho Raises Target Price to $9 From $7
ReutersDec 18 07:10 ET

Comments

Trytosaveabit

20 hours ago

Update

$Verastem (VSTM.US)$ Reuters· 3 mins ago
erastem Oncology Provides a Clinical Update for Ramp 203 Trial in Advanced Kras G12C Mutant Non-Small Cell Lung Cancer! Seen no dose limiting toxicities

Tonyco

Nov 29 13:05

$Verastem (VSTM.US)$
If you had bought on 10/31 my last comment, you'd be up 30% now, grats

Tonyco

Oct 31 22:49

$Verastem (VSTM.US)$
Pretty damn good run so far. I only managed to hop on in Sept.

Jaguar8

Oct 31 15:01

NEWS

$Verastem (VSTM.US)$
Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
Verastem Oncology (VSTM) has completed its rolling New Drug Application (NDA) to the FDA for avutometinib plus defactinibcombination therapy for adults with recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC). The company is seeking accelerated approval and priority review, with a potential FDA ap...

Overall

No Data